ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% – Fierce Pharma
- ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBC
- Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer statnews.com
- Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Yahoo Finance
- Lung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg.com
المصدر: Google News — US
0
مشاهدة
